Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cy...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2013/317190 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562865193615360 |
|---|---|
| author | Franklin C. Lee William Harris Heather H. Cheng Jaideep Shenoi Song Zhao Junfeng Wang Thomas Champion Jason Izard John L. Gore Michael Porter Evan Y. Yu Jonathan L. Wright |
| author_facet | Franklin C. Lee William Harris Heather H. Cheng Jaideep Shenoi Song Zhao Junfeng Wang Thomas Champion Jason Izard John L. Gore Michael Porter Evan Y. Yu Jonathan L. Wright |
| author_sort | Franklin C. Lee |
| collection | DOAJ |
| description | Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011. Outcomes of interest included those with complete response (pT0) and any response (≤pT1). Odds ratios were calculated using multivariate logistic regression. Results. Compared to those who did not receive neoadjuvant chemotherapy, there were more patients with complete response (28% versus 9%, OR 3.11 (95% CI: 1.45–6.64), P=0.03) and any response (52% versus 25%, OR 3.23 (95% CI: 1.21–8.64), P=0.01). Seventy-two patients received GC (n=41) or MVAC (n=31). CR was achieved in 29% and 22% of GC and MVAC patients, respectively (multivariate OR 0.39, 95% CI 0.10–1.58). Any response (≤pT1) was achieved in 56% of GC and 45% of MVAC patients (multivariate OR 0.45, 95% CI 0.12–1.71). Conclusions. We observed similar pathologic response rates for GC and MVAC neoadjuvant chemotherapy in this cohort of patients with muscle invasive urothelial cancer (MIBC). Our findings support the use of GC as an alternative regimen in the neoadjuvant setting. |
| format | Article |
| id | doaj-art-385a4c3c44ac4e0883ebe1425ce84c4b |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-385a4c3c44ac4e0883ebe1425ce84c4b2025-02-03T01:21:37ZengWileyAdvances in Urology1687-63691687-63772013-01-01201310.1155/2013/317190317190Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder CancerFranklin C. Lee0William Harris1Heather H. Cheng2Jaideep Shenoi3Song Zhao4Junfeng Wang5Thomas Champion6Jason Izard7John L. Gore8Michael Porter9Evan Y. Yu10Jonathan L. Wright11Department of Urology, University of Washington School of Medicine, Seattle, WA 98195, USADivision of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USADivision of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USAGroup Health Permanente, Seattle, WA 98109, USADivision of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USAHuntsman Cancer Institute, Division of Medical Oncology, The University of Utah, Salt Lake City, UT 84112, USADepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195, USADepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195, USADepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195, USADepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195, USADivision of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USADepartment of Urology, University of Washington School of Medicine, Seattle, WA 98195, USAObjectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011. Outcomes of interest included those with complete response (pT0) and any response (≤pT1). Odds ratios were calculated using multivariate logistic regression. Results. Compared to those who did not receive neoadjuvant chemotherapy, there were more patients with complete response (28% versus 9%, OR 3.11 (95% CI: 1.45–6.64), P=0.03) and any response (52% versus 25%, OR 3.23 (95% CI: 1.21–8.64), P=0.01). Seventy-two patients received GC (n=41) or MVAC (n=31). CR was achieved in 29% and 22% of GC and MVAC patients, respectively (multivariate OR 0.39, 95% CI 0.10–1.58). Any response (≤pT1) was achieved in 56% of GC and 45% of MVAC patients (multivariate OR 0.45, 95% CI 0.12–1.71). Conclusions. We observed similar pathologic response rates for GC and MVAC neoadjuvant chemotherapy in this cohort of patients with muscle invasive urothelial cancer (MIBC). Our findings support the use of GC as an alternative regimen in the neoadjuvant setting.http://dx.doi.org/10.1155/2013/317190 |
| spellingShingle | Franklin C. Lee William Harris Heather H. Cheng Jaideep Shenoi Song Zhao Junfeng Wang Thomas Champion Jason Izard John L. Gore Michael Porter Evan Y. Yu Jonathan L. Wright Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Advances in Urology |
| title | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer |
| title_full | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer |
| title_fullStr | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer |
| title_full_unstemmed | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer |
| title_short | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer |
| title_sort | pathologic response rates of gemcitabine cisplatin versus methotrexate vinblastine adriamycin cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer |
| url | http://dx.doi.org/10.1155/2013/317190 |
| work_keys_str_mv | AT franklinclee pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT williamharris pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT heatherhcheng pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT jaideepshenoi pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT songzhao pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT junfengwang pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT thomaschampion pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT jasonizard pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT johnlgore pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT michaelporter pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT evanyyu pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer AT jonathanlwright pathologicresponseratesofgemcitabinecisplatinversusmethotrexatevinblastineadriamycincisplatinneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancer |